Roquefort Therapeutics plc
ROQ.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £200 | £0 | £1 |
| % Growth | -100% | – | -100% | – |
| Cost of Goods Sold | £16 | £4 | £0 | £10 |
| Gross Profit | -£16 | £200 | £0 | -£9 |
| % Margin | – | 100% | – | -1,300.4% |
| R&D Expenses | £153 | £620 | £319 | £1 |
| G&A Expenses | £943 | £1,510 | £941 | £376 |
| SG&A Expenses | £943 | £1,510 | £941 | £501 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £125 |
| Other Operating Expenses | £0 | £0 | £374 | £0 |
| Operating Expenses | £1,096 | £2,130 | £1,634 | £501 |
| Operating Income | -£1,112 | -£1,934 | -£1,634 | -£511 |
| % Margin | – | -966.8% | – | -71,038.8% |
| Other Income/Exp. Net | -£103 | £1 | £0 | -£407 |
| Pre-Tax Income | -£1,215 | -£1,932 | -£1,634 | -£917 |
| Tax Expense | £243 | -£188 | -£19 | £0 |
| Net Income | -£972 | -£1,745 | -£1,615 | -£917 |
| % Margin | – | -872.3% | – | -127,598.5% |
| EPS | -0.008 | -0.014 | -0.016 | -0.037 |
| % Growth | 44.4% | 13.5% | 58% | – |
| EPS Diluted | -0.008 | -0.014 | -0.016 | -0.037 |
| Weighted Avg Shares Out | 129,574 | 129,150 | 103,479 | 24,702 |
| Weighted Avg Shares Out Dil | 130,034 | 129,150 | 103,479 | 24,702 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £1 | £0 | £0 |
| Interest Expense | £98 | £0 | £0 | £0 |
| Depreciation & Amortization | £5 | £4 | £1,634 | £383 |
| EBITDA | -£1,112 | -£1,928 | £0 | -£352 |
| % Margin | – | -964.2% | – | -49,012.9% |